Dose-dependent pharmacokinetics of furosemide in the rat
β Scribed by Dr. M. M. Hammarlund; L. K. Paalzow
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 628 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The pharmacokinetics of furosemide were investigated in the rat at doses of 10 and 40mg kg^β1^ corresponding to doses of 80 and 320 mg given to humans based on body surface area. A threeβcompartment open model with renal excretion taking place from the shallow peripheral compartment gave the best fit to the data. The terminal halfβlife of furosemide was found to change from 29min for the 10 mg kg^β1^ dose to 49min for the 40 mg kg^β1^ dose. This change could be detected as a change in the apparent volume of distribution caused by decreased protein binding at increasing plasma concentrations of furosemide. The total plasma clearance did not change significantly although metabolic and renal clearances both changed. The renal clearance was found to be dependent on the free fraction of furosemide in plasma and thus increased with increasing plasma concentrations. The metabolic clearance decreased with increasing dose indicating a saturable metabolism of furosemide.
π SIMILAR VOLUMES
Flurbiprofen is a chiral 2-arylpropionate used clinically as a racemate. Previously a significant pharmacokinetic interaction between the enantiomers of flurbiprofen has been reported in both rats and humans. The possible mechanism for this interaction was believed to involve competitive protein bin
Furosemide solution was orally administered to 21 healthy adult males to determine dose proportionality over the dose range used and the reproducibility of disposition following a repeated dose. Furosemide solution was given in doses of 20,40, and 80mg, with the 40 mg dose repeated once. Blood was c
The pharmacokinetics of one of the most widely used non-steroidal antiinflammatory drugs, naproxen, were studied in 28 healthy human volunteers at the two most commonly used dose levels, viz., 250 mg and 500 mg, in a cross-over design. The plasma levels of naproxen were analysed by a modified high-p